|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||4.1100 - 4.2250|
|52 Week Range||1.5200 - 9.2000|
|Beta (3Y Monthly)||-0.24|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Shares of CBD company CV Sciences jumped 10% on a deal with retailer Kroger to sell its oils in nearly 1,000 stores.
Illinois became the first state to approve approved recreational marijuana use for adults by legislature, as opposed to a voter referendum.
CV Sciences, Inc. (CVSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Horizons is the company behind the Horizons Marijuana Life Sciences Index ETF (TSX: HMMJ)(OTC: HMLSF), which is one of the world's largest cannabis ETFs. “HMUS will be the first ETF in the world that is solely focused on providing exposure to companies with significant business activities in, or significant exposure to, the United States marijuana or hemp industries,” according to a statement.
Earlier this month, CV Sciences Inc (OTCMKTS: CVSI) released their financial results for the fiscal year ending on Dec. 31, 2018, posting record growth in both revenue and retail distribution. Indeed, CV Sciences finished out the fiscal year with a particularly strong fourth quarter. One of CV Sciences most popular product lines is PlusCBD Gold, which contains high concentrations of CBD instead of a mixture of CBD, CBDA, and other hemp-derived cannabinoids.
The U.S. Hemp Authority, an industry group responsible for the U.S. Hemp Authority Certification Program, announced the first awards of its Certification Seal Friday to companies meeting standards for ...
Repeat performances could be in store for these big marijuana winners from last year.
Martin Sumichrast, CEO of Level Brands, which Plans to Acquire cbdMD By John Jannarone With the passing of the Farm Bill Thursday, major U.S. retailers are likely to pounce on the opportunity to stock their shelves with CBD products after waiting years for such legal clarity. That’s according Level Brands CEO Martin Sumichrast, whose company […]
The 2018 Farm Bill will restore industrial hemp to nationwide legal production for the first time since World War II, offering vast opportunities for the industry and investment in a market expected to triple in four years. With the removal of hemp from federal prohibition under the Controlled Substances Act of 1970 (CSA), the total U.S. hemp industry now looks to expand at a healthy 18.4% through a 5-year combined annual growth rate (CAGR) from 2018-2022. New Frontier Data’s Hemp Business Journal estimates that, in leading all hemp product categories, the hemp-derived CBD market will grow from a $390 million-dollar market in 2018, to a $1.3 billion market (or 3.3x) by 2022, representing a 27.2% 5-year CAGR.
Pending President Trump’s signature next week, the 2018 Farm Bill is poised to restore industrial hemp to nationwide legal production for the first time since World War II, offering vast opportunities for the industry and investment in a market expected to triple in four years. With removal of hemp from federal prohibition under the Controlled Substances Act of 1970 (CSA), the total U.S. hemp industry now looks to expand at a healthy 18.4% through a 5-year combined annual growth rate (CAGR) from 2018-2022. Hemp Business Journal estimates that, in leading all hemp product categories, the hemp-derived CBD market will grow from a $390 million-dollar market in 2018, to a $1.3 billion market (3.3x) by 2022, representing a 27.2% 5-year CAGR.
The 2018 Farm Bill was passed by the Senate on Tuesday by a vote of 87-13. The next move is that the legislation heads to the House for a vote -- and then if it passes there, it goes to President Trump to be signed into law. The impact of this legislation on the cannabis industry is enormous.
Level Brands to Acquire cbdMD in All Stock Transaction By John Jannarone Level Brands is betting the farm on hemp. The company, which went public in 2017 as a licensing vehicle for Kathy Ireland’s kathy ireland Worldwide, announced this week it would acquire Cure Based Development LLC, owner of consumer cannabidiol (CBD) brand cbdMD. […]
CV Sciences, somewhat incredibly, has risen by a factor of 21x in just the last year. CVSI stock, in fact, has risen more than 1,000% just since April. Unlike a number of OTC marijuana-related stocks, CV Sciences has a real business.
When the market is volatile, investors flee to safety. Often, investors will retreat out of growth names and into more established industries. We saw that trend play out in October on the over-the-counter ...
Naturally, this has significant implications for marijuana stocks. Favorable legislation stateside and in Canada boosted marijuana stocks like Tilray (NASDAQ:TLRY) into the stratosphere. While the pain is extremely pronounced for pot stocks, I believe the political environment presents high-risk/high-reward contrarian opportunities.
Nearly every publicly traded cannabis company is in a clear downtrend at the moment, as the major market indices have given back their 2018 gains. VantagePoint’s artificial intelligence and intermarket analysis signals make 1-3 day forecasts accurate up to 86 percent of the time. The chart below is a three-month chart of CVSI, where each candle represents one day of trading.
One question for American investors is how that affects U.S. marijuana stocks? What happened in Canada changes little in the U.S. The federal ban on marijuana remains in place. Yes, recreational and medical marijuana are legal in nine states and 31 states respectively.
U.S. Marijuana Index, compiled by Marijuana International Corporation, has delivered 158% returns over the past one year, as of October 17, 2018. Though the market saw a lot of volatility in marijuana policy during the course of the year on account of hard line policy stance taken by the new U.